SNSE Overview

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. The Company's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The Company is also completing a Phase I/II trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Its TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Its programs include Solnerstotug (SNS-101), SNS-102, SNS-103, and SNS-201. Solnerstotug is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1.

Wall Street analysts forecast SNSE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNSE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Sensei Biotherapeutics Inc revenue for the last quarter amounts to -4.96M USD, decreased -32.31

Sensei Biotherapeutics Inc. EPS for the last quarter amounts to -3864000.00 USD, decreased -33.29

Sensei Biotherapeutics Inc (SNSE) has 29 emplpoyees as of April 20 2026.

Today SNSE has the market capitalization of 40.87M USD.